"Thromboplastin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
| Descriptor ID |
D013925
|
| MeSH Number(s) |
D12.776.124.125.900 D23.119.965
|
| Concept/Terms |
Thromboplastin- Thromboplastin
- Coagulin
- Factor III
- Glomerular Procoagulant Activity
- Activity, Glomerular Procoagulant
- Procoagulant Activity, Glomerular
- Prothrombinase
- CD142 Antigens
- Tissue Factor Procoagulant
- Procoagulant, Tissue Factor
- Tissue Thromboplastin
- Thromboplastin, Tissue
- Urothromboplastin
- Blood Coagulation Factor III
- Antigens, CD142
- Coagulation Factor III
- Factor III, Coagulation
- Tissue Factor
|
Below are MeSH descriptors whose meaning is more general than "Thromboplastin".
Below are MeSH descriptors whose meaning is more specific than "Thromboplastin".
This graph shows the total number of publications written about "Thromboplastin" by people in this website by year, and whether "Thromboplastin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 9 | 5 | 14 |
| 2018 | 5 | 6 | 11 |
| 2019 | 4 | 3 | 7 |
| 2020 | 2 | 1 | 3 |
| 2021 | 2 | 7 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Thromboplastin" by people in Profiles.
-
Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus. J Thromb Haemost. 2021 11; 19(11):2652-2658.
-
Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. Transfus Apher Sci. 2021 Dec; 60(6):103237.
-
SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase. Blood. 2021 07 29; 138(4):344-349.
-
Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J Thromb Haemost. 2021 09; 19(9):2268-2274.
-
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis. J Thromb Thrombolysis. 2021 10; 52(3):689-691.
-
Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns. J Intern Med. 2021 09; 290(3):677-692.
-
Response by Mackman et al to Letter Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report". Arterioscler Thromb Vasc Biol. 2021 06; 41(6):e381-e382.
-
Letter by Brambilla et al Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report". Arterioscler Thromb Vasc Biol. 2021 06; 41(6):e379-e380.
-
Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients. Front Immunol. 2021; 12:664209.
-
Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection. EBioMedicine. 2021 May; 67:103369.